A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. by Iavarone, C, Ramsauer, K, Kubarenko, A, Debasitis, J, Leykin, I, Weber, A, Siggs, O, Beutler, B, Zhang, P, Otten, G, D'Oro, U, Valiante, N, Mbow, M, Visintin, A

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference by Bast, RCJ, Matulonis, UA, Sood, AK, Ahmed, A, Amobi, AE, Balkwill, FR, Wielgos-Bonvallet, M, Bowtell, DDL, Brenton, JD, Brugge, JS, Coleman, RL, Draetta, GF, Doberstein, K, Drapkin, RI, Eckert, MA, Edwards, RP, Elias, KM, Ennis, D, Futreal, A, Gershenson, DM, Greenberg, RA, Huntsman, DG, Ji, JXY, Kohn, EC, Iavarone, C, Lengyel, ER, Levine, DA, Lord, CJ, Lu, Z, Mills, GB, Modugno, F, Nelson, BH, Odunsi, K, Pilsworth, JA, Rottapel, RK, Powell, DJJ, Shen, L, Shih, LM, Spriggs, DR, Walton, J, Zhang, K, Zhang, R, Zou, L